

# Current Topics in Microbiology and Immunology

Volume 383

## Series editors

Rafi Ahmed

School of Medicine, Rollins Research Center, Emory University, Room G211, 1510 Clifton Road, Atlanta, GA 30322, USA

Klaus Aktories

Medizinische Fakultät, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Abt. I, Albert-Ludwigs-Universität Freiburg, Albertstr. 25, 79104 Freiburg, Germany

Richard W. Compans

Department of Microbiology and Immunology, Emory University, 1518 Clifton Road, CNR 5005, Atlanta, GA 30322, USA

Max D. Cooper

Department of Pathology and Laboratory Medicine, Georgia Research Alliance, Emory University, 1462 Clifton Road, Atlanta, GA 30322, USA

Jorge E. Galan

Boyer Ctr. for Molecular Medicine, School of Medicine, Yale University, 295 Congress Avenue, room 343, New Haven, CT 06536-0812, USA

Yuri Y. Gleba

ICON Genetics AG, Biozentrum Halle, Weinbergweg 22, 06120 Halle, Germany

Tasuku Honjo

Faculty of Medicine, Department of Medical Chemistry, Kyoto University, Sakyo-ku, Yoshida, Kyoto 606-8501, Japan

Yoshihiro Kawaoka

School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA

Bernard Malissen

Centre d'Immunologie de Marseille-Luminy, Parc Scientifique de Luminy, Case 906, 13288, Marseille Cedex 9, France

Michael B. A. Oldstone

Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Rino Rappuoli

Novartis Vaccines, Via Fiorentina 1, Siena 53100, Italy

Peter K. Vogt

Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, BCC-239, La Jolla, CA 92037, USA

Honorary Editor: Hilary Koprowski (deceased)

Formerly at Biotechnology Foundation, Inc., Ardmore, PA, USA

More information about this series at <http://www.springer.com/series/82>

Jeremy Nuttall  
Editor

# Microbicides for Prevention of HIV Infection

Responsible Series Editor: Hilary Koprowski

 Springer

*Editor*  
Jeremy Nuttall  
Preclinical Sciences and Product  
Development  
International Partnership for Microbicides  
Silver Spring, MD  
USA

ISSN 0070-217X                      ISSN 2196-9965 (electronic)  
ISBN 978-3-662-44595-2            ISBN 978-3-662-44596-9 (eBook)  
DOI 10.1007/978-3-662-44596-9

Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2014947134

© Springer-Verlag Berlin Heidelberg 2014

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

# Preface

More than 30 years after the first cases were reported, the HIV/AIDS pandemic remains a global health priority. Heterosexual transmission of HIV accounts for 70–80 % of infections worldwide, and women are disproportionately affected by this disease, especially in sub-Saharan Africa where they account for approximately 60 % of infections. In developing countries, factors such as low acceptance of condoms, patterns of sexual behavior, social attitude, viral loads in the semen of the HIV-positive partner, local viral subtypes, and coinfection with other sexually transmitted disease mean that exposure to an infected partner is much more likely to result in transmission than in developed countries, with women again the most affected. There are also anatomical and physiological factors that put women at a greater risk of infection than men. In addition, social, legal, and economic disadvantages make women more likely to become HIV infected.

In order to change the course of the HIV pandemic, effective strategies for prevention of HIV transmission are critical. Abstinence, reducing the number of sexual partners and concurrent sexual relationships, and correct, consistent condom use has been found to be effective in reducing the probability of HIV infection. However, these methods have proven to be insufficient to control infection rates. More HIV prevention strategies are required that provide options for those populations who need protection the most. Thus, safe and effective HIV prevention methods, particularly those that are female-controlled, could play a major role in reducing the incidence of HIV-1 transmission.

In recent years, a number of biomedical interventions have shown promise in HIV prevention. These include pre-exposure prophylaxis (PrEP), treatment as prevention, and microbicides. The concept of microbicides as an HIV prevention strategy was first introduced in an article titled ‘HIV Prevention: The Need for Methods Women Can Use’ published in April 1990. Microbicides are topical products that can be applied vaginally or rectally to protect the user from acquiring HIV and, possibly, other STIs.

Early microbicides were nonspecific compounds that worked by either disrupting the viral envelope (e.g., surfactants), electrostatically blocking the virus from interacting with target cells in the vagina (e.g., polyanions), or by maintaining the low pH of the vagina, making it inhospitable to HIV. All of these microbicides were formulated as gels that were intended to be applied vaginally just prior to sex. Clinical trials of these early candidates all failed to demonstrate efficacy, which led to an increased focus on products based on more potent and highly specific antiretroviral compounds. These microbicides are able to be formulated in a wider range of dosage forms, including formulations for daily use and sustained release products for use over a month or more, and can incorporate combinations of active ingredients that may improve their effectiveness further. In 2010, the microbicide field achieved its first proof of concept when a vaginal gel containing 1 % tenofovir was shown to protect women by 39 %.

The development of microbicides is a long and complicated process, with many challenges in product design, in the conduct and design of clinical trials, and in obtaining licensure for a new class of products intended for use almost exclusively in developing countries. This edition of *Current Topics in Microbiology and Immunology* is entirely dedicated to the field of microbicides. It is intended to cover all the critical areas associated with the development of microbicides, from the selection of appropriate candidate molecules, their formulation, preclinical and clinical testing for safety and efficacy, strategies for product registration and finally, issues associated with product launch, distribution, and access.

The authors were all selected because of their expertise in the development of microbicides. Consequently, much of the information is derived directly from their personal experience over years of product development, and is supplemented with knowledge gained from the experience of colleagues in the field. Since no microbicide product has yet been brought to market, some of the information presented represents what is believed rather than proven to be best practice, but reflects the current state of the art and the techniques, models, procedures, and processes available. However, researchers, developers, advocates, and regulators are together learning more about the transmission process and how to prevent it, determining what will be necessary to get these products to market, and how this can best be achieved.

My hope is that this edition will prove valuable to both workers in the microbicide field and others who are interested in learning more about this promising intervention that has the potential to significantly impact the future of the devastating HIV/AIDS epidemic. Whilst it is not possible to cover every aspect of microbicide development in detail, efforts have been made to point the reader toward other sources of information that may be helpful in filling any gaps and providing a more comprehensive understanding of the issues associated with microbicide development.

I would like to thank all the authors for the high quality of their contributions, and their patience and support in putting this edition together. I would also like to acknowledge the team at the International Partnership for Microbicides, and colleagues in many other organizations whose collaborations have helped move the field forward to the point where we now have products that are in the final stages of development, and are moving ever closer to getting them into the hands of those that so desperately need them.

Jeremy Nuttall

# Contents

<b>Candidate Microbicides and Their Mechanisms of Action</b> . . . . .	1
Carolina Herrera and Robin J. Shattock	
<b>Microbicide Dosage Forms</b> . . . . .	27
L. C. Rohan, B. Devlin and H. Yang	
<b>Preclinical Safety Evaluation</b> . . . . .	55
Jonathon D. S. Holt and Jeremy P. Nuttall	
<b>Clinical Safety and Pharmacology Trial</b> . . . . .	79
Christine Mauck, Andrea Thurman and Jill Schwartz	
<b>Microbicides for Prevention of HIV Infection:</b>	
<b>Clinical Efficacy Trials</b> . . . . .	97
Salim S. Abdool Karim and Cheryl Baxter	
<b>Rectal Microbicide Development</b> . . . . .	117
Ian McGowan and Charlene Dezzutti	
<b>Developing Regulatory Strategy for Microbicides</b> . . . . .	137
Ronald Nardi, Linda Arterburn and Lisa Carlton	
<b>Preparing for Microbicide Introduction, Rollout, and Sustained Access</b> . . . . .	153
Cynthia Woodsong, Elizabeth McGrory and Tim Farley	
<b>Index</b> . . . . .	177